John Kearney, General Manager UK and Ireland at Amgen, takes up post as President of the Association of the British Pharmaceutical Industry (ABPI) today, following his formal appointment at the Association’s Annual General Meeting yesterday.
An economics graduate, John has been on the Board of the ABPI since 2008 where he has worked on a number of key initiatives including leading the Association’s pricing team in negotiations with the Department of Health to secure the 2014 PPRS.
John has 35 years of experience in the pharmaceutical industry – holding UK and international roles at GlaxoSmithKline and international roles at Pfizer before joining Amgen in 2007. He replaces Jonathan Emms, former UK Managing Director of Pfizer, who is relocating to the US following an internal promotion.
“It is a privilege to be nominated as President of the ABPI and I take up the role from Jonathan with great pleasure,” said John. “Jonathan’s leadership of the past 12 months has steered the industry through a challenging 2014 and I am honoured to pick up the baton as we move into 2015 and the opportunities and challenges of an election year.
“I intend to tackle these challenges and capitalise on the opportunities – working with industry, Government and the NHS – for the benefit of patients.” Welcoming John to the role, Alison Clough ABPI’s Executive Director Commercial UK said: “We are delighted to welcome John to his new role. Having worked closely with John as a Board member for a number of years I am pleased now to be working alongside John as President. His unique experience and expertise across the industry will be crucial as he leads the ABPI and the UK pharmaceutical industry through the coming year.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: